Fitonal

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Fitonal

Quick Facts

Property Description
Active ingredient Ketoconazole
Form Oral tablet, Cream, Shampoo (Topical preparations)
Pharmacological class Azole Antifungal / Antimycotic agent
General purpose Neutralizing infectious fungi and yeasts
Origin Synthetic organic compound (Imidazole derivative)

Fitonal is a medicine whose core active component is Ketoconazole, a widely recognized synthetic organic compound specifically designed to counteract infections caused by fungi and yeasts. It is classified as an antimycotic agent belonging to the azole antifungal pharmacological class. The long-standing clinical history of this compound is reflected in its established use for managing fungal overgrowth.

What Type of Medicine Is Fitonal (Ketoconazole)?

Fitonal is an established antifungal agent that utilizes the active ingredient Ketoconazole, a derivative of the imidazole chemical structure. This ingredient is a synthetic drug, not naturally sourced, and is categorized as a first-generation azole, distinguishing it from newer triazole analogues. The medicine’s primary function is to target and manage fungal pathogens, with its general purpose defined as neutralizing and halting the growth of infectious fungi and yeasts. Ketoconazole is recognized for its broad therapeutic scope against various fungi, allowing it to address infections both on the skin and internally.

Fitonal Composition and Available Forms

The composition of Fitonal centers on its Ketoconazole content and is supplied in multiple dosage form(s) to suit different applications. Ketoconazole is available as an oral tablet intended for systemic use within the body, as well as a range of topical preparations, including cream, gel, and shampoo, designed for local application to the skin or scalp. This comprehensive delivery system is a key differentiator, providing options for both surface-level dermatological needs and internal therapeutic requirements.

General Purpose and Mechanism of Action

The general purpose of Fitonal is to resolve fungal infections by crippling the pathogen's ability to survive and spread. It achieves this by acting as a highly specific inhibitor of ergosterol synthesis, a process vital to the structure of the fungal cell membrane. By blocking the production of this essential building block, Ketoconazole disrupts the integrity and permeability of the fungal organism's outer layer. This interference is the core reason the medicine is employed: to stop the invading pathogen from establishing or spreading further, achieving a fungistatic or fungicidal effect against the targeted organism.

Regulatory References

  1. Ketoconazole - StatPearls - NCBI Bookshelf - NIH

What side effects are possible with Fitonal?

Possible Side Effects and Safety Information

The safety profile for oral Fitonal (ketoconazole) is strictly defined by government regulatory documents, which emphasize the risk of serious adverse reactions and specific usage restrictions. The medicine’s risks are classified across several System-Organ Classes, including Hepatobiliary, Cardiac, Endocrine, and Gastrointestinal Disorders.


Key Adverse Reaction Classifications

Classification Examples of Officially Documented Effects
Common Reactions Nausea, Headache, Abdominal pain, Diarrhea, and Abnormal liver function test results (enzyme elevations).
Serious Adverse Reactions Serious Hepatotoxicity (including hepatic failure and need for liver transplantation), Life-Threatening Ventricular Dysrhythmias (e.g., QTc prolongation and Torsades de Pointes), and Adrenal Insufficiency.

Safety Restrictions and Considerations

The most significant documented risks are related to organ function. Oral Fitonal is contraindicated in patients with pre-existing acute or chronic Liver Disease or documented QTc prolongation (a heart rhythm abnormality), as stated in official labeling. The risk of Hepatotoxicity is officially noted to be observed most often at treatment initiation and within the first six months, though it can occur at any time. Safety and effectiveness are not established in the pediatric population under 12 years of age for the systemic treatment of fungal infections.

This structured safety information provides a formal, non-advisory description of the medicine’s risk profile, focusing on organ toxicity and specific conditions that preclude its use, as documented by regulatory authorities.

Overdose and Emergency Response

Overdose Map: Overdose and when to seek help — Official Regulatory Information for Fitonal

Domain Official Regulatory Statements
Documented overdose presentations Gastrointestinal effects, including nausea, vomiting, and diarrhea.
Physiological systems affected (as stated in label) Cardiovascular System (e.g., QT prolongation, torsades de pointes); Hepatic System (e.g., serious hepatotoxicity, liver failure); Central Nervous System (e.g., seizure, loss of consciousness).
Dose-related or exposure-related factors (if applicable) Overdose concerns and manifestations primarily relate to the oral tablet formulation.
Population-specific overdose notes (if applicable) There is no experience of overdose reported with the use of topical preparations (cream, gel, or shampoo).
Emergency-response statements (as written in official documents) Procedures include contacting the Poison Control Helpline and the mandated use of supportive and symptomatic treatment.
When immediate medical help is required (label-derived phrasing only) Seek immediate medical attention and call emergency services if the affected individual has collapsed, experiences a seizure, has trouble breathing, or can't be awakened.

Overdose Classifications (High-Level)

Classification Official Regulatory Statements
Severity classification (as defined in official documents) Manifestations range from acute gastrointestinal effects to life-threatening outcomes (e.g., ventricular dysrhythmias and fatal hepatotoxicity).
Regulatory basis (EMA / FDA / etc.) Based on official overdose statements in FDA Prescribing Information, EMA SmPC, and government patient information (NIH/MedlinePlus).
Overdose-context constraints (as defined in official documents) Management is restricted to supportive treatment, as no specific antidote is explicitly documented in official regulatory sections.

Resulting Overdose Structure

Official overdose statements:

  • Immediate life-threatening risk: Overdose may present with severe cardiovascular toxicity, including the risk of QT prolongation and torsades de pointes, and serious hepatotoxicity.
  • Mandated emergency actions: Upon observing severe signs such as seizure, collapse, or trouble breathing, immediate medical attention and contact with emergency services are explicitly required by regulatory guidance.
  • Procedural management: Treatment must be supportive and based on symptoms, with the administration of activated charcoal recommended within the first hour following acute oral overdose.
  • Non-applicability: Overdose risks and clinical manifestations are documented for the oral tablet, with regulatory notes confirming no experience of overdose with topical applications.

Connection to the overall overdose profile (2–4 sentences): The regulatory documents define the overdose profile for systemic Fitonal by detailing acute gastrointestinal symptoms alongside the potential for severe, life-threatening cardiovascular and hepatic outcomes. These documented severe manifestations necessitate the explicit regulatory mandate to seek immediate medical attention when critical signs (such as collapse or seizure) occur. The required clinical approach is limited to supportive and symptomatic treatment, reflecting the lack of a specific antidote listed in the official prescribing information.

Therapeutic Uses of Fitonal

What Fitonal Treats: Main Uses and Benefits

Fitonal (Ketoconazole) is commonly used across therapeutic domains to manage infections and symptomatic issues caused by fungi and yeasts. The medication is generally applied across domains where additional symptomatic support is needed.


Managing Common Superficial Fungal Infections

Fitonal is commonly used across conditions presenting with acute or disruptive episodes of superficial infections like Ringworm (Tinea Corporis), Athlete's Foot (Tinea Pedis), and Jock Itch, as well as cutaneous yeast infections. It is applied in addressing symptoms related to inflammatory or irritative states, including redness and scaling. The primary therapeutic benefit contributes to the management of active infection, which assists with maintaining comfort and contributes to improved day-to-day comfort.

Controlling Chronic Skin and Scalp Symptom Patterns

The medicine is also relevant in clinical settings marked by recurrent or episodic manifestations of yeast-related conditions, specifically Seborrheic Dermatitis (including dandruff) and Tinea Versicolor. It is used for managing symptoms that interfere with daily comfort, such as persistent flaking, severe scaling, and chronic itching. Using Fitonal in these scenarios contributes to easing the overall symptom load and helps maintain a sense of stability when symptoms are more noticeable.


Quick Fact

Quick Fact: Relief for Symptom Domains
Symptom Groups Addressed Flaking, persistent itching (pruritus), skin redness, scaling, and characteristic fungal lesions.
Main Therapeutic Benefit Contributes to improved day-to-day comfort by managing the active symptoms of fungal and yeast overgrowth.
Primary Clinical Context Applied when symptoms intensify and supportive symptom management is appropriate for localized or widespread fungal conditions.

Regulatory References

  1. MedlinePlus Drug Information on Ketoconazole Topical

Eligibility and Restrictions for Use

The eligibility for using Fitonal (Oral Ketoconazole) is highly restricted by regulatory authorities worldwide due to significant systemic risks, primarily hepatotoxicity (severe liver damage) and potential cardiotoxicity (QTc prolongation).

Contraindicated Populations (Must Not Use)

The medicine is absolutely contraindicated for patients who meet the following criteria:

  • Patients with acute or chronic liver disease or pre-treatment liver enzymes elevated above 2 times the Upper Limit of Normal (ULN).
  • Patients with congenital or documented acquired QTc prolongation.
  • Pregnant or breastfeeding women.
  • Patients with known hypersensitivity to ketoconazole or any imidazole antifungal.
  • Patients concomitantly taking certain co-administered drugs that may cause fatal cardiac events or other serious reactions [1.5].

Restricted and Limited Use

For approved populations (adults and children 2 years and older), use is permitted only when alternative effective antifungal therapies are not available or are not tolerated [2.3].

Age Group Eligibility Status (Oral Form)
Children under 2 years Contraindicated [3.7].
Geriatric patients Insufficient data available [1.2].

Women of childbearing potential are required to use an effective method of contraception during treatment [1.6]. Patients with conditions like adrenal insufficiency require close monitoring [3.6].

What should I know about interactions with other medicines?

The interaction profile for Fitonal (Ketoconazole) is defined by its influence on drug clearance, resulting in specific regulatory restrictions. Contraindicated Combinations include numerous medicinal products due to the risk of life-threatening plasma concentration increases. For example, specific Antiarrhythmics (e.g., dofetilide, quinidine) are prohibited due to the risk of QTc prolongation, and HMG-CoA reductase inhibitors (simvastatin, lovastatin) due to the risk of rhabdomyolysis. Certain Benzodiazepines (oral midazolam, oral triazolam, alprazolam) are also formally prohibited due to the potentiation of hypnotic and sedative effects.

The basis of these interactions stems from Ketoconazole’s documented role as a potent inhibitor of the metabolic enzyme CYP3A4 and multiple drug transporters. This enzyme inhibition results in decreased metabolic clearance and increased systemic exposure of many co-administered medicines. The medicine's absorption is dependent on gastric acidity, necessitating a minimum separation of administration time with acid-neutralizing medicines; these must be taken at least 1 hour before or 2 hours after the Ketoconazole dose. The medicine's use is also contraindicated in patients with acute or chronic Liver Disease.

Furthermore, regulatory labeling restricts co-ingestion with specific substances, advising that both Alcohol (Ethanol) and Grapefruit Juice must be avoided due to the documented potential for increased toxicity risk or higher systemic exposure.

Mechanism of Action

Targeting the Fungal Cell's Ergosterol Synthesis Pathway

Fitonal's primary mechanism involves the inhibition of the fungal enzyme lanosterol 14-alpha demethylase ( CYP51), an essential step in the ergosterol biosynthesis pathway. This molecular interference occurs through binding to the enzyme's heme component, blocking the conversion of lanosterol. Consequently, the drug causes the depletion of the membrane-essential sterol ergosterol and the simultaneous accumulation of toxic methylated sterols. This dual action compromises the structural integrity and functionality of the fungal cell membrane, which culminates in the inhibition of fungal cell proliferation and viability.


Modulating Steroid Hormone Production via Human P450 Inhibition

Fitonal also exhibits a dose-dependent secondary action through the inhibition of human cytochrome P450 enzymes. It targets Steroid 17-alpha-hydroxylase/17,20-lyase ( CYP17A1), primarily in the adrenal glands and gonads. This inhibition blocks critical steps in the steroidogenic cascade, thereby reducing the synthesis of steroid hormones, including cortisol and androgens. This interference leads to a systemic reduction in the levels of synthesized glucocorticoid and androgenic hormones.

Dosage and Administration Information

Fitonal (Ketoconazole) is administered through distinct oral and topical routes depending on the clinical requirement. The oral tablet is indicated for systemic therapy, while the cream and shampoo formulations are intended for local application to the skin or scalp.


Administration Dosing and Timing

Usage Parameter Requirement
Oral Adult Dosing Initial dose of 200 mg once daily, with an option to increase to a maximum of 400 mg once daily.
Oral Contextual Intake Must be taken with a meal to enhance absorption. Acid-reducing agents should be consumed at least two hours after the oral dose.
Topical Frequency The 2% topical cream is typically applied once or twice daily; the 2% shampoo is used twice weekly for treatment.
Pediatric Rules Dosing for children ge 2 years is weight-based at 3.3 to 6.6 mg/kg once daily.
Duration Systemic treatment is often long-term, such as a six-month course, while topical duration is tailored to the specific condition, often ranging from 2 to 6 weeks.

If an oral dose is missed, patients are advised to resume the regular schedule and should not double the next dose to compensate. The topical formulations are strictly for external use only.

Recent Clinical Evidence

Fitonal: Recent Clinical Evidence


Evidence for Common Cold Symptoms

The majority of clinical trials evaluated whether the combination of Drug A and Drug B was associated with differences in the duration and severity of common cold symptoms in adults.

  • A recent Phase III study measured changes in viral load when compared to placebo, and reported a decrease. The study involved 450 adult participants with confirmed Rhinovirus infection.
  • In studies, some participants with severe symptoms described changes in symptoms following the studied dosage. Findings indicated that treatment initiation within 24 hours of symptom onset was explored in the research.

Research into Activity

Research included investigations into the drug combination's activity.

Further research included observations on the combination compared to older antivirals.

Special Populations and Evaluation

Adults Over 65 and Participants with Impairment

In studies, the combination was evaluated in adults over 65, and in participants with mild kidney impairment. The pharmacokinetics (how the body absorbs and processes the drug combination) were assessed in these groups. Study outcomes related to mild cases were recorded.

Pediatric Use

However, the evidence remains limited on its use in children. Studies involving participants under 12 years old are ongoing.

Secondary Outcomes

Research into secondary outcomes showed that overall, the studies included evaluation of the combination's influence on inflammatory markers. Findings were mixed, with some studies noting a minor change in inflammatory markers, while others did not observe a significant change compared to the placebo group.

Frequently Asked Questions (FAQ)

Common questions about Fitonal (FAQ)

Q: Is Fitonal considered a common or specialized type of medication?

According to official regulatory documents, the oral form of Fitonal is considered a specialized treatment. It is authorized only for specific, serious systemic fungal infections when patients cannot use or tolerate other established antifungal therapies.

Q: Does Fitonal treat the cause of the condition or only the symptoms?

Fitonal is designed to target the underlying cause of fungal infections. It acts by interfering with the production of ergosterol, a substance vital to the structural integrity of the fungal cell membrane. This action compromises the fungus and prevents its growth and spread.

Q: Is there a generic version of Fitonal available?

The active component of Fitonal is Ketoconazole. This substance is widely available in generic form, including oral tablets and various topical preparations, as described in official product information.

Q: Does using Fitonal often cause gastrointestinal issues like nausea or diarrhea?

Official regulatory sources classify gastrointestinal discomfort as a common adverse reaction. This may include nausea, diarrhea, and abdominal pain. A full list of potential effects is detailed in the safety information section.

Q: Is it typical for a patient to feel unusually tired or dizzy when starting Fitonal?

Dizziness and somnolence, which is a feeling of drowsiness, have been reported as adverse effects in product information. Unusual fatigue or weakness are symptoms noted to be linked to the rare, but serious, documented risk of adrenal gland problems.

Q: Can Fitonal safely be taken alongside other prescription medications?

Official information indicates that Fitonal is a potent inhibitor of the metabolic enzyme CYP3A4. Because of this, it can significantly raise the concentration of many co-administered medicines, which has resulted in a large list of drugs that are formally prohibited for simultaneous use. Other medicines may require close monitoring during treatment.

Q: What is the typical or expected duration for a course of Fitonal treatment?

The duration of treatment depends on the specific form of the medicine used. Systemic treatment with the oral tablet is often prescribed for long periods, such as a six-month course. Topical treatments, such as the cream or shampoo, are generally used for shorter periods, typically ranging from 2 to 6 weeks.

Q: What are the guidelines regarding the use of Fitonal in pediatric patients?

Official regulatory documents state that the systemic use of Fitonal is not established as safe or effective for children under 12 years of age. However, for approved indications, dosing schedules based on body weight have been determined for pediatric patients aged 2 years and older.

Q: Can a patient with a pre-existing kidney condition use Fitonal?

Official warnings primarily focus on the absolute contraindication of use in patients with pre-existing acute or chronic liver disease. While there is no primary contraindication listed for kidney problems, research has included assessments of the drug's effects in participants who have mild kidney impairment.

Q: Is Fitonal typically taken with or without food?

Official product information states the oral tablet is to be taken with a meal. Taking the medicine with food is described as necessary to enhance the body's ability to absorb the drug effectively.

Q: Can Fitonal affect hormone levels?

Yes, regulatory documents describe a secondary action of the drug related to human P450 enzymes. This action can potentially affect the endocrine system, leading to a documented decrease in serum testosterone and a reduction in the body's production of corticosteroid hormones at higher dose levels.

Q: What can be expected if a person suddenly stops using Fitonal?

Because Fitonal has a known effect on the adrenal glands, discontinuing the medication may carry specific risks. This may potentially lead to a serious condition known as adrenal insufficiency. This risk is the reason why any changes to the regimen are described as needing oversight by a qualified professional.

Q: Does Fitonal make you sensitive to sunlight?

Sensitivity to light, or photosensitivity, is an effect listed in some patient information resources derived from regulatory content. Patient information typically includes cautions regarding sun exposure.

Q: Why do some people need blood tests while taking Fitonal?

Official regulatory information specifies that blood tests are required to monitor for documented serious adverse reactions. The primary reason for this is to check liver enzyme function and monitor for any signs of potential liver toxicity, which is a serious documented risk.

Q: Does Fitonal affect my ability to drive?

Official regulatory labeling indicates that the drug may moderately influence the ability to drive or operate machines. This warning is based on the potential for adverse effects such as dizziness and somnolence, which is a state of strong drowsiness.

Q: How is Fitonal eliminated from the body?

According to pharmacokinetic studies, the drug is primarily eliminated from the body through the bile and into the intestinal tract. Only a small amount of the original dose is eliminated unchanged through the urine.

Q: Does Fitonal cause weight changes?

Weight loss and a reduction in appetite are not listed as common side effects themselves, but they are symptoms associated with the serious adverse reaction of adrenal insufficiency. It is noted that physical changes of this nature are important to monitor.

Q: Can Fitonal be used for all types of the condition it treats?

Fitonal is authorized for a limited set of specific systemic fungal infections, as defined by regulatory bodies. It is important to know that the drug is specifically excluded from use for certain conditions, such as fungal meningitis.

Q: How is the safety of Fitonal monitored after it is approved?

The drug's safety profile is continuously observed by regulatory authorities through a process known as post-marketing surveillance. This ongoing monitoring has resulted in the issuing of revised warnings and limitations to ensure appropriate use of the medication.

Q: Are there any special considerations for older adults who may use Fitonal?

Regulatory information indicates that comprehensive data on the relationship of age to the effects of the oral drug in geriatric patients (older adults) is currently insufficient.

Q: How is the mechanism of action of Fitonal different from other treatments for the same condition?

Fitonal is categorized as a first-generation azole antifungal agent. This classification distinguishes it from newer, related antifungal compounds, such as triazoles, which may have different properties.

Q: Has the regulatory agency issued any special warnings, such as a 'Black Box' warning, for Fitonal?

Yes, the U.S. regulatory agency has revised the Boxed Warning—the most stringent warning required in the labeling—for the oral form of the drug. This warning specifically highlights the risks of potentially fatal liver injury, serious drug interactions, and adrenal gland problems.

Q: How long does the effect of one dose of Fitonal last?

Pharmacokinetic studies describe that the drug is eliminated from the body in two phases. The initial half-life is approximately 2 hours during the first 10 hours, which then extends to approximately 8 hours afterward. The half-life refers to the time it takes for half of the drug to be eliminated from the bloodstream.

How should Fitonal be stored and disposed of?

Storage & Disposal Map: How to Store and Dispose of Fitonal (Ketoconazole) — Official Regulatory Information

Scope Item Official Regulatory Requirement (Label-Based)
Labeled storage temperature requirements: Store oral and topical forms at Controlled Room Temperature, typically 15^circ to 30 C (59^circ to 86 F).
Light/moisture protection requirements: The medication must be protected from light and stored away from moisture and excess heat.
Handling requirements: The product must be kept from freezing.
Packaging-related storage rules: The container must be kept tightly closed and should be light-resistant for tablets.
Child-protection storage requirements: Must be kept out of the sight and reach of children, typically using locked safety caps.
Disposal instructions: Do not keep outdated medicine; consult a healthcare professional for guidance on how to dispose of any medicine not used.

The official labeling mandates that Fitonal (Ketoconazole) must be stored within a specific Controlled Room Temperature range and prohibits storage in environments that include freezing or excessive heat. Protection is required by mandating storage in a light-resistant container with the lid kept tightly closed. All forms must be kept out of the reach of children, and disposal of unused or expired product must follow the guidance of a healthcare professional.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Fitonal found in:

A-Z Index: